Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti‐<scp>PD</scp>‐1 <scp>mAb</scp> treated recurrent/metastatic squamous cell carcinoma of the head and neck patients
Dan P. Zandberg(University of Pittsburgh Medical Center), Rivka R. Colen(The University of Texas MD Anderson Cancer Center), Priyadarshini Mamindla(University of Pittsburgh), Vishal Peddagangireddy(University of Pittsburgh), Şerafettin Zenkin(University of Pittsburgh), Umamaheswar Duvvuri(City University of New York), Ronan W. Hsieh(UPMC Hillman Cancer Center), Murat Ak(University of Pittsburgh Medical Center), Robert L. Ferris(University of Pittsburgh), Greg M. Delgoffe(University of Pittsburgh), Jennifer L. Anderson(University of Pittsburgh Medical Center), Ashely Menk(UPMC Hillman Cancer Center), Heath D. Skinner(University of Pittsburgh)
Cited by 5
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2
|Nature Immunology|2011|1.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688